Gene Editing for Cystic Fibrosis
September 21, 2021 | Terry Sharrer

Evaluating CRISPR-based prime editing for cancer modeling
“Prime editing is a recently reported genome editing tool using a nickase-cas9 fused to a reverse transcriptase that directly synthesizes the desired edit at the target site. Here, we [Hubrecht Institute, Utrecht, Netherlands] explore the use of prime editing in human organoids. . . . we functionally repaired the cystic fibrosis CFTR-F508del mutation and compared prime editing to CRISPR/Cas9–mediated homology-directed repair and adenine base editing on the CFTR-R785* mutation. Whole-genome sequencing of prime editing–repaired organoids revealed no detectable off-target effects.” MORE
Image Credit: Life-science-alliance.org